celecoxib has been researched along with Bilateral Headache in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Indomethacin-responsive headaches encompass a group of disorders which include a subset of the trigeminal autonomic cephalalgias and other paroxysmal, often precipitated primary headaches." | 8.12 | Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders. ( Bahra, A; Farag, M, 2022) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 6.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| "Indomethacin-responsive headaches encompass a group of disorders which include a subset of the trigeminal autonomic cephalalgias and other paroxysmal, often precipitated primary headaches." | 4.12 | Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders. ( Bahra, A; Farag, M, 2022) |
| " We report four cases of hemicrania continua and a patient suffering chronic paroxysmal hemicrania completely responsive to celecoxib." | 3.76 | Are Cox-2 drugs the second line option in indomethacin responsive headaches? ( Cuadrado, M; García-Ptacek, S; Porta-Etessam, J; Rodríguez-Gómez, O; Valencia, C, 2010) |
| "This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily." | 2.73 | Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. ( Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C, 2007) |
| "Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group." | 2.72 | [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 2.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| "We concluded that cerebrovascular diseases (CD) can lead to ISH and that the COX-2 inhibitor can be an effective prophylactic drug for ISH after CD." | 1.31 | COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases. ( Kowacs, PA; Piovesan, EJ; Werneck, LC; Zukerman, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farag, M | 1 |
| Bahra, A | 1 |
| Chau, C | 1 |
| Chu, EC | 1 |
| Huang, KH | 1 |
| Tam, D | 1 |
| Cheung, G | 1 |
| Xu, C | 1 |
| Gu, K | 1 |
| Yasen, Y | 1 |
| Hou, Y | 1 |
| Rossi, P | 1 |
| Tassorelli, C | 1 |
| Allena, M | 1 |
| Ferrante, E | 1 |
| Lisotto, C | 1 |
| Nappi, G | 1 |
| Porta-Etessam, J | 1 |
| Cuadrado, M | 1 |
| Rodríguez-Gómez, O | 1 |
| García-Ptacek, S | 1 |
| Valencia, C | 1 |
| Sheng, JQ | 1 |
| Li, SR | 1 |
| Yang, XY | 1 |
| Zhang, YH | 1 |
| Su, H | 1 |
| Yu, DL | 1 |
| Yan, W | 1 |
| Geng, HG | 1 |
| Schwartz, JI | 1 |
| Thach, C | 1 |
| Lasseter, KC | 1 |
| Miller, J | 1 |
| Hreniuk, D | 1 |
| Hilliard, DA | 1 |
| Snyder, KM | 1 |
| Gertz, BJ | 1 |
| Gottesdiener, KM | 1 |
| Piovesan, EJ | 1 |
| Zukerman, E | 1 |
| Kowacs, PA | 1 |
| Werneck, LC | 1 |
2 reviews available for celecoxib and Bilateral Headache
| Article | Year |
|---|---|
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Abdominal Pain; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Diarrhea; Dyspepsia; Headache; | 2016 |
Focus on therapy: hemicrania continua and new daily persistent headache.
Topics: Amines; Analgesics; Celecoxib; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fructose; Gaba | 2010 |
2 trials available for celecoxib and Bilateral Headache
| Article | Year |
|---|---|
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agent | 2007 |
4 other studies available for celecoxib and Bilateral Headache
| Article | Year |
|---|---|
Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Headache; Headache Disorders; Humans | 2022 |
Remission of Dowager's hump by manipulative correction of spinal alignment: a case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Female; Headache; Humans; Kyp | 2023 |
Are Cox-2 drugs the second line option in indomethacin responsive headaches?
Topics: Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Headache; Humans; Male; Middle Aged; Pa | 2010 |
COX-2 inhibitor for the treatment of idiopathic stabbing headache secondary to cerebrovascular diseases.
Topics: Aged; Brain Ischemia; Celecoxib; Cerebrovascular Disorders; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2002 |